MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Jan. 11, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) announced that Larry Jasinski, Chief Executive Officer, and Mike Lawless, Chief Financial Officer, will provide an overview presentation and host one-on-one meetings with investors at the Sidoti January Virtual Investor Conference, taking place on January 17-18, 2024.
The presentation will begin at 2:30 PM EST on January 17, 2024 and can be accessed live here. ReWalk will also host virtual one-on-ones with investors on Wednesday and Thursday, January 17-18, 2023. Registration is available to interested investors for the presentation or one-on-ones at www.sidoti.com/events. Registration is free and interested investors do not need to be a Sidoti client.
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. is a medical device company that designs, develops, and commercializes innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions. ReWalk’s mission is to fundamentally change the quality of life for these individuals through the creation and development of market leading technologies. Through its recent acquisition of AlterG, Inc., ReWalk has added anti-gravity systems to its growing portfolio of products. Founded in 2001, ReWalk has operations in the United States, Israel, and Germany. For more information on the ReWalk systems, please visit rewalk.com. For more information on the AlterG systems, please visit alterg.com.
ReWalk® and ReStore® are registered trademarks of ReWalk Robotics Ltd. in the United States and other jurisdictions. AlterG® is a registered trademark of AlterG, Inc. in the United States and other jurisdictions.
ReWalk Investor Contact:
Michael Lawless
Chief Financial Officer
ReWalk Robotics Ltd.
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
ReWalk Media Relations:
LifeSci Communications
E: This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$0.68 |
| Daily Change: | -0.03 -4.31 |
| Daily Volume: | 590,814 |
| Market Cap: | US$12.380M |
December 03, 2025 November 17, 2025 November 14, 2025 September 08, 2025 August 14, 2025 | |

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load